Literature DB >> 33612571

Visceral leishmaniasis masquerading as drug-induced pancytopenia in myasthenia gravis.

Uttam Kumar Nath1, Debmalya Bhattacharyya2, Debranjani Chattopadhya1, Gaurav Dhingra1, Shweta Azad3, Aroop Mohanty4.   

Abstract

Visceral leishmaniasis (VL), also known as kala-azar (black fever in Hindi), is a disease primarily caused by Leishmania donovani. The most important clinical manifestation of visceral leishmaniasis is fever. Nonspecific laboratory findings of visceral leishmaniasis include anemia, neutropenia, eosinopenia, and thrombocytopenia. Definitive diagnosis of visceral leishmaniasis requires the demonstration of either parasite by smear or tissue by culture (usually bone marrow or spleen). Myasthenia gravis is an autoimmune disease caused by antibodies to acetylcholine receptors in the post-junctional membrane of the neuromuscular junction. It typically presents with fatigable muscle weakness without any sensory or brain involvement. It is usually treated with corticosteroids and immunosuppressants like azathioprine. Here we encountered a confirmed case of myasthenia gravis on azathioprine with pancytopenia. While working up to evaluate pancytopenia, bone marrow examination revealed presence of Donovan bodies and the patient showed good response to liposomal amphotericin-B. In retrospect, a case of myasthenia gravis, who presented with pancytopenia presumably drug-induced, was found to have visceral leishmaniasis.

Entities:  

Keywords:  Immunosuppression; myasthenia gravis; pancytopenia; visceral leishmaniasis

Year:  2021        PMID: 33612571     DOI: 10.5582/ddt.2020.03101

Source DB:  PubMed          Journal:  Drug Discov Ther        ISSN: 1881-7831


  1 in total

1.  Global prevalence of myasthenia gravis and the effectiveness of common drugs in its treatment: a systematic review and meta-analysis.

Authors:  Nader Salari; Behnaz Fatahi; Yalda Bartina; Mohsen Kazeminia; Reza Fatahian; Payam Mohammadi; Shamarina Shohaimi; Masoud Mohammadi
Journal:  J Transl Med       Date:  2021-12-20       Impact factor: 5.531

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.